GSK plc (LON:GSK) Receives Consensus Recommendation of "Hold" from Analysts

Key Points

• Analysts have a consensus recommendation of “Hold” on GSK from seven brokerages (1 sell, 3 hold, 3 buy), with an average 1‑year price target of GBX 2,016.43 and notable upgrades such as Citigroup raising its target to GBX 2,250 and assigning a buy rating.
• Shares opened at GBX 2,124; GSK has a market cap of £84.89bn, a PE ratio of 15.30, and a 52‑week range of GBX 1,242.50–2,282, with the 50‑ and 200‑day SMAs at GBX 2,082.10 and GBX 1,866.78 respectively.
• Insider activity shows recent buying — insiders purchased 11,447 shares worth about $24.27m in the last 90 days, including Jonathan Symonds’ acquisition of 5,000 shares at GBX 1,951.

Shares of GSK plc (LON:GSK - Get Free Report) have been given a consensus recommendation of "Hold" by the seven brokerages that are presently covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is GBX 2,016.43.

GSK has been the subject of several research analyst reports. Deutsche Bank Aktiengesellschaft upped their price target on shares of GSK from GBX 1,600 to GBX 1,675 and gave the company a "hold" rating in a research report on Thursday, January 15th. JPMorgan Chase & Co. restated an "underweight" rating on shares of GSK in a research report on Wednesday, January 7th. UBS Group restated a "neutral" rating and issued a GBX 1,940 price target on shares of GSK in a research report on Friday, January 23rd. Berenberg Bank restated a "hold" rating and issued a GBX 2,000 price target on shares of GSK in a research report on Thursday, March 26th. Finally, Citigroup upped their price target on shares of GSK from GBX 1,900 to GBX 2,250 and gave the company a "buy" rating in a research report on Monday, February 9th.

GSK Stock Up 1.3%

Shares of LON:GSK opened at GBX 2,124 on Wednesday. The company has a debt-to-equity ratio of 108.20, a quick ratio of 0.73 and a current ratio of 0.82. The company has a market cap of £84.89 billion, a PE ratio of 15.30, a price-to-earnings-growth ratio of 1.24 and a beta of 0.35. GSK has a 52 week low of GBX 1,242.50 and a 52 week high of GBX 2,282. The firm has a 50 day simple moving average of GBX 2,082.10 and a 200 day simple moving average of GBX 1,866.78.

GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Wednesday, February 4th. The company reported GBX 172 EPS for the quarter. GSK had a net margin of 17.50% and a return on equity of 37.19%. As a group, research analysts expect that GSK will post 175.980975 earnings per share for the current year.

Insider Activity at GSK

In related news, insider Anne Beal acquired 196 shares of the company's stock in a transaction on Friday, March 20th. The shares were purchased at an average price of GBX 5,179 per share, for a total transaction of £10,150.84. Also, insider Jonathan Symonds acquired 5,000 shares of the company's stock in a transaction on Friday, March 20th. The stock was bought at an average price of GBX 1,951 per share, for a total transaction of £97,550. Insiders have bought a total of 11,447 shares of company stock worth $24,273,097 in the last 90 days. 0.20% of the stock is owned by corporate insiders.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.